Synaffix inks $246m deal with ProfoundBio
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Die Stada Arzneimittel AG zahlt im Rahmen eines EU-Marketingabkommens für Nefecon zur Behandlung der IgA-Nephropathie vorab 20 Mio. Euro an die Calliditas Therapeutics AB.
Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
NeuVasQ Biotechnologies has raised 20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.